Three-dimensional tumor model as a robust platform for in vivo testing of cancer therapies
Manu Smriti Singh
Despite major investments and research in the field of nanomedicine, there have been few nanocarriers that saw therapeutic success in clinical settings. The difference outcomes in patients has been assigned to the tumor pathophysiology, which is also a function of blood vasculature and varies across clinical tumor types. The routine tumor models in mice wherein single cells are injected en masse (monolayer grown 2D cells) do not emulate the growth of naturally occurring tumors. In our current work, we developed robust mice 3D spheroid model by implantation of pre-formed mini-tumors in contrast to the routinely used 2D model. As representatives of drug, nanoparticle and antibody treatments we chose- Doxorubicin, Doxil and Avastin to test on the two models. To elucidate the difference in response to the treatments, we characterized the two tumor models and established that they differed characteristically with respect to blood vasculature (Endothelial cells) and stroma (Myofibroblasts) and the ensuing tumor microenvironment (TME) dynamics.
Share this article